Bristol-Myers Squibb (NYSE:BMY), is regarded as an industry leader in biotechnology and pharma. BMY manufactures prescription pharmaceuticals in therapeutic areas including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. Opdivo is its number one revenue generating product, an immune system stimulating cancer drug first approved for squamous non-small cell lung cancer with several indications for different cancers some approved and some still being investigated, making up to 60% of BMY market cap. Opdivo and Eliquis, a blood anticoagulant, combine to yield over 40% of BMY revenues and both will be under patent exclusivity for at least 5 more years.
